JP7629649B2 - Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法 - Google Patents

Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法 Download PDF

Info

Publication number
JP7629649B2
JP7629649B2 JP2022515824A JP2022515824A JP7629649B2 JP 7629649 B2 JP7629649 B2 JP 7629649B2 JP 2022515824 A JP2022515824 A JP 2022515824A JP 2022515824 A JP2022515824 A JP 2022515824A JP 7629649 B2 JP7629649 B2 JP 7629649B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
seq
antigen
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022515824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547551A (ja
JP2022547551A5 (https=
Inventor
ワ－ン，チャオ
ナッセンツワイグ，ミッシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2022547551A publication Critical patent/JP2022547551A/ja
Publication of JP2022547551A5 publication Critical patent/JP2022547551A5/ja
Application granted granted Critical
Publication of JP7629649B2 publication Critical patent/JP7629649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022515824A 2019-09-11 2020-09-11 Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法 Active JP7629649B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (3)

Publication Number Publication Date
JP2022547551A JP2022547551A (ja) 2022-11-14
JP2022547551A5 JP2022547551A5 (https=) 2023-09-07
JP7629649B2 true JP7629649B2 (ja) 2025-02-14

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515824A Active JP7629649B2 (ja) 2019-09-11 2020-09-11 Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法

Country Status (7)

Country Link
US (1) US20220315645A1 (https=)
EP (1) EP4021503A4 (https=)
JP (1) JP7629649B2 (https=)
KR (1) KR20220080102A (https=)
CN (1) CN114728066A (https=)
CA (1) CA3154556A1 (https=)
WO (1) WO2021050954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107126A1 (en) 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500515A (ja) * 1986-06-20 1989-02-23 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
KR20150070181A (ko) * 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107126A1 (en) 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Also Published As

Publication number Publication date
EP4021503A4 (en) 2024-02-14
CA3154556A1 (en) 2021-03-18
JP2022547551A (ja) 2022-11-14
WO2021050954A1 (en) 2021-03-18
EP4021503A1 (en) 2022-07-06
CN114728066A (zh) 2022-07-08
KR20220080102A (ko) 2022-06-14
US20220315645A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
JP7171809B2 (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
Wang et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations
Hehle et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
CN113929771A (zh) 多瘤病毒中和抗体
JP2019528050A (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
CN107921285A (zh) 多价乙型肝炎病毒抗原结合分子及其应用
WO2022015573A2 (en) Sars-cov-2 antigen-binding proteins and uses thereof
JP2018533937A (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
JP2022507836A (ja) 新規の抗ジカウイルス抗体及びその使用
WO2018184593A1 (zh) 用于治疗乙肝感染及相关疾病的抗体
JP7629649B2 (ja) Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法
JP2023503714A (ja) 抗ｅ－セレクチン抗体、組成物および使用の方法
TWI904172B (zh) 抗hbv抗體及使用方法
AU2017313632A2 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
JP7847753B2 (ja) Ｂ型肝炎ウイルス（ｈｂｖ）のヒト肝細胞への感染を阻害できるヒトｎｔｃｐに結合する抗体
KR102769097B1 (ko) 항-b형 간염 바이러스 항체 및 이의 용도
RU2844736C1 (ru) Антитела к hbv и способы применения
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
US20240327500A1 (en) Anti-hbv antibodies and uses thereof
Beretta et al. In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus
Wang et al. Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity
HK40059983A (en) Polyomavirus neutralizing antibodies
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
BR112015022988B1 (pt) Anticorpo monoclonal isolado antagonista do interferon alfa e ômega, seu uso e composição farmacêutica compreendendo o referido anticorpo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250127

R150 Certificate of patent or registration of utility model

Ref document number: 7629649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150